Examining the effects of furosemide on toxin levels in chronic kidney disease patients
Official title: The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease
Run by UMC Utrecht · NCT06750575 · Data updated 2026-11-12
This study is testing whether the diuretic furosemide affects the levels of certain toxins in the blood and urine of people with chronic kidney disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 34 (estimated) |
| Sponsor | UMC Utrecht Academic / other |
| Locations | 1 site (Utrecht, Utrecht) |
| Status | Recruiting |
| Started | June 10, 2024 |
| Main results expected | July 1, 2025 |
| Study ends | July 1, 2025 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT06750575 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with CKD stage 3-5 and an indication for furosemide treatment.
✕Probably not a fit
Patients already on furosemide, those with liver disease, or those requiring renal replacement therapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how the diuretic furosemide affects the plasma levels and urinary excretion of protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). Participants will be monitored before and after starting furosemide treatment, with blood and urine samples collected to assess changes in PBUT levels. The study aims to clarify whether furosemide increases PBUT levels by reducing their renal excretion, which could have implications for patient health. The design includes invasive measurements and a prospective repeated measures approach.
Why it matters
Potential benefit: If successful, this study could lead to improved management of toxin levels in CKD patients, potentially reducing morbidity and mortality.
How similar studies have gone: While the interaction between furosemide and PBUTs is not extensively studied, similar approaches in managing CKD have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * An age of 18 years or older * An eGFR \<60 mL/min/1.73m2 for at least three months (diagnosis of CKD stage 3-5) * An indication for the start of treatment with furosemide as part of routine patient care * Willingness to participate in the study and a signed informed consent Exclusion Criteria: * Patients who are already on furosemide treatment * Patients with a liver disease with hyperbilirubinemia * Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis) * Patients with end-stage renal failure without residual diuresis * Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding * Patients who are incapacitated
Where it's running
-
University Medical Center Utrecht (UMCU)
Utrecht, Utrecht, Netherlands Recruiting
Study contacts
- Principal investigator: Karin GF Gerritsen, MD, PhD — UMC Utrecht
- Study coordinator: Dian P Bolhuis, MD, MSc
- Email: d.p.bolhuis-3@umcutrecht.nl
- Phone: +31-887557375
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.